Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register

Gary J Macfarlane, Ross I R MacDonald, Ejaz Pathan, Stefan Siebert, Karl Gaffney, Ernest Choy, Jon Packham, Kathryn R Martin, Kirstie Haywood, Raj Sengupta, Fabiola Atzeni, Gareth T Jones

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To quantify the extent to which co-morbid FM is associated with higher disease activity, worse quality of life (QoL) and poorer response to TNF inhibitors (TNFis) in patients with axial SpA.

Methods: A prospective study recruiting across 83 centres in the UK. Clinical information and patient-reported measures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting the FM criteria on disease activity, QoL and response to TNFis.

Results: A total of 1757 participants were eligible for analyses, of whom 22.1% met criteria for FM. Those with co-morbid FM criteria had higher disease activity [BASDAI average difference FM+ - FM- 1.04 (95% CI 0.75, 1.33)] and worse QoL [Ankylosing Spondylitis Quality of Life score difference 1.42 (95% CI 0.88, 1.96)] after adjusting for demographic, clinical and lifestyle factors. Among 291 participants who commenced biologic therapy, BASDAI scores in those with co-morbid FM were 2.0 higher at baseline but decreased to 1.1 higher at 12 months. There was no significant difference in the likelihood of meeting Assessment of SpondyloArthritis international Society 20 criteria at 12 months. Less improvement in disease activity and QoL over 3 months of TNFi therapy was most strongly related to high scores on the FM criteria symptom severity scale component.

Conclusion: Fulfilling criteria for FM has a modest impact on the assessment of axial SpA disease activity and QoL and does not significantly influence response to biologic therapy. Those with a high symptom severity scale on FM assessment may benefit from additional specific management for FM.

Original languageEnglish
Pages (from-to)1982-1990
Number of pages9
JournalRheumatology
Volume57
Issue number11
Early online date20 Jul 2018
DOIs
Publication statusPublished - 30 Nov 2018

Keywords

  • Adult
  • Aged
  • Antirheumatic Agents/therapeutic use
  • Female
  • Fibromyalgia/complications
  • Humans
  • Male
  • Middle Aged
  • Registries
  • Severity of Illness Index
  • Spondylarthritis/complications
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha/antagonists & inhibitors
  • United Nations

Cite this

Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis : results from a UK national register. / Macfarlane, Gary J; MacDonald, Ross I R; Pathan, Ejaz; Siebert, Stefan; Gaffney, Karl; Choy, Ernest; Packham, Jon; Martin, Kathryn R; Haywood, Kirstie; Sengupta, Raj; Atzeni, Fabiola; Jones, Gareth T.

In: Rheumatology, Vol. 57, No. 11, 30.11.2018, p. 1982-1990.

Research output: Contribution to journalArticle

Macfarlane, GJ, MacDonald, RIR, Pathan, E, Siebert, S, Gaffney, K, Choy, E, Packham, J, Martin, KR, Haywood, K, Sengupta, R, Atzeni, F & Jones, GT 2018, 'Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register', Rheumatology, vol. 57, no. 11, pp. 1982-1990. https://doi.org/10.1093/rheumatology/key206
Macfarlane, Gary J ; MacDonald, Ross I R ; Pathan, Ejaz ; Siebert, Stefan ; Gaffney, Karl ; Choy, Ernest ; Packham, Jon ; Martin, Kathryn R ; Haywood, Kirstie ; Sengupta, Raj ; Atzeni, Fabiola ; Jones, Gareth T. / Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis : results from a UK national register. In: Rheumatology. 2018 ; Vol. 57, No. 11. pp. 1982-1990.
@article{7333e36f9751452a8b7db23390acf50a,
title = "Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register",
abstract = "Objective: To quantify the extent to which co-morbid FM is associated with higher disease activity, worse quality of life (QoL) and poorer response to TNF inhibitors (TNFis) in patients with axial SpA.Methods: A prospective study recruiting across 83 centres in the UK. Clinical information and patient-reported measures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting the FM criteria on disease activity, QoL and response to TNFis.Results: A total of 1757 participants were eligible for analyses, of whom 22.1{\%} met criteria for FM. Those with co-morbid FM criteria had higher disease activity [BASDAI average difference FM+ - FM- 1.04 (95{\%} CI 0.75, 1.33)] and worse QoL [Ankylosing Spondylitis Quality of Life score difference 1.42 (95{\%} CI 0.88, 1.96)] after adjusting for demographic, clinical and lifestyle factors. Among 291 participants who commenced biologic therapy, BASDAI scores in those with co-morbid FM were 2.0 higher at baseline but decreased to 1.1 higher at 12 months. There was no significant difference in the likelihood of meeting Assessment of SpondyloArthritis international Society 20 criteria at 12 months. Less improvement in disease activity and QoL over 3 months of TNFi therapy was most strongly related to high scores on the FM criteria symptom severity scale component.Conclusion: Fulfilling criteria for FM has a modest impact on the assessment of axial SpA disease activity and QoL and does not significantly influence response to biologic therapy. Those with a high symptom severity scale on FM assessment may benefit from additional specific management for FM.",
keywords = "Adult, Aged, Antirheumatic Agents/therapeutic use, Female, Fibromyalgia/complications, Humans, Male, Middle Aged, Registries, Severity of Illness Index, Spondylarthritis/complications, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors, United Nations",
author = "Macfarlane, {Gary J} and MacDonald, {Ross I R} and Ejaz Pathan and Stefan Siebert and Karl Gaffney and Ernest Choy and Jon Packham and Martin, {Kathryn R} and Kirstie Haywood and Raj Sengupta and Fabiola Atzeni and Jones, {Gareth T}",
year = "2018",
month = "11",
day = "30",
doi = "10.1093/rheumatology/key206",
language = "English",
volume = "57",
pages = "1982--1990",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis

T2 - results from a UK national register

AU - Macfarlane, Gary J

AU - MacDonald, Ross I R

AU - Pathan, Ejaz

AU - Siebert, Stefan

AU - Gaffney, Karl

AU - Choy, Ernest

AU - Packham, Jon

AU - Martin, Kathryn R

AU - Haywood, Kirstie

AU - Sengupta, Raj

AU - Atzeni, Fabiola

AU - Jones, Gareth T

PY - 2018/11/30

Y1 - 2018/11/30

N2 - Objective: To quantify the extent to which co-morbid FM is associated with higher disease activity, worse quality of life (QoL) and poorer response to TNF inhibitors (TNFis) in patients with axial SpA.Methods: A prospective study recruiting across 83 centres in the UK. Clinical information and patient-reported measures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting the FM criteria on disease activity, QoL and response to TNFis.Results: A total of 1757 participants were eligible for analyses, of whom 22.1% met criteria for FM. Those with co-morbid FM criteria had higher disease activity [BASDAI average difference FM+ - FM- 1.04 (95% CI 0.75, 1.33)] and worse QoL [Ankylosing Spondylitis Quality of Life score difference 1.42 (95% CI 0.88, 1.96)] after adjusting for demographic, clinical and lifestyle factors. Among 291 participants who commenced biologic therapy, BASDAI scores in those with co-morbid FM were 2.0 higher at baseline but decreased to 1.1 higher at 12 months. There was no significant difference in the likelihood of meeting Assessment of SpondyloArthritis international Society 20 criteria at 12 months. Less improvement in disease activity and QoL over 3 months of TNFi therapy was most strongly related to high scores on the FM criteria symptom severity scale component.Conclusion: Fulfilling criteria for FM has a modest impact on the assessment of axial SpA disease activity and QoL and does not significantly influence response to biologic therapy. Those with a high symptom severity scale on FM assessment may benefit from additional specific management for FM.

AB - Objective: To quantify the extent to which co-morbid FM is associated with higher disease activity, worse quality of life (QoL) and poorer response to TNF inhibitors (TNFis) in patients with axial SpA.Methods: A prospective study recruiting across 83 centres in the UK. Clinical information and patient-reported measures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting the FM criteria on disease activity, QoL and response to TNFis.Results: A total of 1757 participants were eligible for analyses, of whom 22.1% met criteria for FM. Those with co-morbid FM criteria had higher disease activity [BASDAI average difference FM+ - FM- 1.04 (95% CI 0.75, 1.33)] and worse QoL [Ankylosing Spondylitis Quality of Life score difference 1.42 (95% CI 0.88, 1.96)] after adjusting for demographic, clinical and lifestyle factors. Among 291 participants who commenced biologic therapy, BASDAI scores in those with co-morbid FM were 2.0 higher at baseline but decreased to 1.1 higher at 12 months. There was no significant difference in the likelihood of meeting Assessment of SpondyloArthritis international Society 20 criteria at 12 months. Less improvement in disease activity and QoL over 3 months of TNFi therapy was most strongly related to high scores on the FM criteria symptom severity scale component.Conclusion: Fulfilling criteria for FM has a modest impact on the assessment of axial SpA disease activity and QoL and does not significantly influence response to biologic therapy. Those with a high symptom severity scale on FM assessment may benefit from additional specific management for FM.

KW - Adult

KW - Aged

KW - Antirheumatic Agents/therapeutic use

KW - Female

KW - Fibromyalgia/complications

KW - Humans

KW - Male

KW - Middle Aged

KW - Registries

KW - Severity of Illness Index

KW - Spondylarthritis/complications

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha/antagonists & inhibitors

KW - United Nations

U2 - 10.1093/rheumatology/key206

DO - 10.1093/rheumatology/key206

M3 - Article

C2 - 30053166

VL - 57

SP - 1982

EP - 1990

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 11

ER -